MaxCyte and Ori Biotech joined forces to optimize manufacturing of autologous cellular therapies by integrating MaxCyte’s ExPERT and flow electroporation technologies with Ori’s IRO platform. This collaboration aims to streamline production workflows, improve yields, and shorten timelines for gene-edited T cell therapies. The partnership employs a test system focusing on CD19 CAR expression via CRISPR knock-in to validate enhanced manufacturing efficiencies. This integration reflects an industry trend toward modular and scalable solutions for accelerating gene and cell therapy commercialization.